Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKinsey
Express Scripts
Medtronic
Dow

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Beloranib

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Beloranib?

Beloranib is an investigational drug.

There have been 8 clinical trials for Beloranib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Syndrome, Prader-Willi Syndrome, and Overweight. The leading clinical trial sponsors are Zafgen, Inc. and [disabled in preview].

There are five US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for Beloranib
TitleSponsorPhase
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes MellitusZafgen, Inc.Phase 2
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi SyndromeZafgen, Inc.Phase 3
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic InjuryZafgen, Inc.Phase 2

See all Beloranib clinical trials

Clinical Trial Summary for Beloranib

Top disease conditions for Beloranib
Top clinical trial sponsors for Beloranib

See all Beloranib clinical trials

US Patents for Beloranib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Beloranib   Start Trial Fumigillol compounds and methods of making and using same Zafgen, Inc. (Boston, MA)   Start Trial
Beloranib   Start Trial Methods of treating a subject with benign prostate hyperplasia Zafgen, Inc. (Cambridge, MA)   Start Trial
Beloranib   Start Trial Fumigillol compounds and methods of making and using same Zafgen, Inc. (Boston, MA)   Start Trial
Beloranib   Start Trial Fumagillol heterocyclic compounds and methods of making and using same Zafgen, Inc. (Boston, MA)   Start Trial
Beloranib   Start Trial Fumigillol compounds and methods of making and using same Zafgen, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Beloranib

Drugname Country Document Number Estimated Expiration Related US Patent
Beloranib Australia 2013259620 2032-05-09   Start Trial
Beloranib Brazil 112014027981 2032-05-09   Start Trial
Beloranib Canada 2873574 2032-05-09   Start Trial
Beloranib China 104364251 2032-05-09   Start Trial
Beloranib European Patent Office 2850079 2032-05-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Medtronic
Express Scripts
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.